2025 Partners
Alloy Therapeutics
Expertise Partner
Alloy’s Keyway TCR Discovery is a proprietary, integrated, end-to-end service for generating highly-specific
therapeutically-optimized TCR mimic leads. From immunizing our industry-leading ATX-Gx mice with high-quality protein-HLA complexes, to pairing in vitro and AI/ML capabilities for broad developability and specificity screening, to state-of-art engineering and bespoke functional screening capabilities. Integrating our discovery capabilities with our expertise in multi specifics engineering, Alloy is well placed to meet the needs of the rapidly developing therapeutic T-Cell Engager field
Invenra
Expertise Partner
Invenra is a leader in antibody discovery and multispecific platform technologies, providing innovative solutions to accelerate and streamline the development of next-generation therapeutics across diverse formats. Our established B-Body® platform enables rapid, high-throughput discovery and generation of robustly manufacturable bispecific antibodies. Building on this success, our new T-Body™ platform is purpose-built for trispecific antibodies, designed to overcome key developability hurdles often faced with complex formats like advanced T-cell engagers through superior expression, efficient assembly, and simplified purification. By integrating proprietary antibody libraries and high-throughput screening methodologies with these versatile ‘Plug & Play’ platforms, Invenra empowers partners to efficiently translate complex biology into effective therapeutic candidates targeting cancer and immune diseases faster and more effectively.
Biocytogen
Exhibition Partner
Biocytogen is a global biotech company advancing antibody drug development through innovative technologies. Leveraging gene-editing expertise, it pioneered drug target knock-in humanized models and offers 3,000+ models via BioMice™, along with in vivo, ex vivo, and in vitro pharmacology and custom gene-editing services. Biocytogen drives fully human monoclonal antibody discovery and offers 400,000+ antibody sequences targeting 1,000 proteins through its RenBiologics™ sub-brand for global partnerships.
ProBio
Event Partner
ProBio, a U.S. subsidiary of GenScript Biotech Corp., has end-to-end capabilities for biologics discovery & development. With facilities in the U.S., Netherlands, South Korea, and China, ProBIo has enabled its global partners to obtain more than 90 IND approvals since 2017.
More recently, ProBio has committed to internally develop antibody-based therapeutics
available for out-licensing, highlighted by the T cell engager candidates derived from our unique CD3 VHH platform.
Towards the mission of “Innovation through Collaboration,” ProBio is committed to helping
partners accelerate the development & commercialization of biologics in order to shape a
healthier future